Intra-Cellular Therapies' lumateperone shows significant efficacy in reducing schizophrenia relapse rates, with a 63% risk ...

The study also included an 18-week open-label phase, during which patients with Schizophrenia were treated with Lumateperone 42 mg per day. The biopharmaceutical company found that the time to relapse ...

Intra-Cellular Therapies’ atypical antipsychotic medication Caplyta has been on a roll, delivering fast commercial growth and coming up triumphant in yet another late-stage trial. | Intra-Cellular ...

Even though psychiatric disorders such as schizophrenia, bipolar disorder, and autism spectrum disorder (ASD) are quite ...

044). Conversely, 6 taxa, such as rhodospirillaceae, defluviitaleaceae, and desulfovibrio, were protective against schizophrenia (OR: 0.88-0.94; P ≤.049). The findings may provide evidence for the ...

Even though psychiatric disorders such as schizophrenia, bipolar disorder, and autism spectrum disorder (ASD) are quite ...

Even though psychiatric disorders such as schizophrenia, bipolar disorder, and autism spectrum disorder (ASD) are quite common, their diagnosis and treatment are challenging. While doctors today have ...

On Tuesday (Nov. 5) the board will be asked to allocate $282,613 to cover staffing positions and overhead costs associated ...

Repeated miscommunications may hint at underlying mental health issues, affecting social cognition and relationships.

As announced in February 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to our New Drug Application (NDA) for roluperidone (f/k/a MIN-101) for the treatment ...

Two new studies and an accompanying short film have described the experiences of racially minoritized groups with physical and mental health conditions during the pandemic, depicting the inequalities ...

Those suffering from schizophrenia and bipolar disorders are more likely ... ensuring they receive the appropriate care and ...